Activity of amoxicillin/clavulanate in patients with tuberculosis
- PMID: 9564467
- DOI: 10.1086/513945
Activity of amoxicillin/clavulanate in patients with tuberculosis
Abstract
Some beta-lactam antibiotics are active in vitro against Mycobacterium tuberculosis. There are anecdotal reports of successful treatment of tuberculosis caused by multiple-drug-resistant strains of M. tuberculosis with regimens that included amoxicillin/clavulanate. Reduction of M. tuberculosis in the sputum of patients with pulmonary tuberculosis during administration of amoxicillin/clavulanate was measured by a quantitative culture method to determine the activity in vivo. Patients were randomized to receive isoniazid, ofloxacin, or amoxicillin/clavulanate for 7 days. Isoniazid was the most effective agent, reducing M. tuberculosis after 2 days at a mean rate (+/- standard deviation) of 0.60 +/- 0.30 log10 cfu/mL per day, compared with 0.32 +/- 0.05 and 0.34 +/- 0.03 for ofloxacin and amoxicillin/clavulanate, respectively. The early bactericidal activity of amoxicillin/clavulanate was comparable to that reported for antituberculous agents other than isoniazid. Further studies of beta-lactam antibiotics with in vitro activity against M. tuberculosis are warranted to define their role in treatment of tuberculosis.
Comment in
-
Beta-lactam drugs and tuberculosis.Clin Infect Dis. 1998 Apr;26(4):878-9. doi: 10.1086/513946. Clin Infect Dis. 1998. PMID: 9564468 No abstract available.
Similar articles
-
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial.Am J Respir Crit Care Med. 2022 May 15;205(10):1228-1235. doi: 10.1164/rccm.202108-1976OC. Am J Respir Crit Care Med. 2022. PMID: 35258443 Free PMC article. Clinical Trial.
-
Amoxicillin-clavulanic acid for treating drug-resistant Mycobacterium tuberculosis.Chest. 1991 Apr;99(4):1025-6. doi: 10.1378/chest.99.4.1025. Chest. 1991. PMID: 1901260
-
Early bactericidal activity of amoxicillin in combination with clavulanic acid in patients with sputum smear-positive pulmonary tuberculosis.Scand J Infect Dis. 2001;33(6):466-9. doi: 10.1080/00365540152029954. Scand J Infect Dis. 2001. PMID: 11450868 Clinical Trial.
-
New drugs for tuberculosis.Eur Respir J Suppl. 1995 Sep;20:714s-718s. Eur Respir J Suppl. 1995. PMID: 8590571 Review.
-
Amoxicillin and amoxicillin plus clavulanate: a safety review.Expert Opin Drug Saf. 2009 Jan;8(1):111-8. doi: 10.1517/14740330802527984. Expert Opin Drug Saf. 2009. PMID: 19236222 Review.
Cited by
-
Imipenem for treatment of tuberculosis in mice and humans.Antimicrob Agents Chemother. 2005 Jul;49(7):2816-21. doi: 10.1128/AAC.49.7.2816-2821.2005. Antimicrob Agents Chemother. 2005. PMID: 15980354 Free PMC article.
-
Early Bactericidal Activity of Meropenem plus Clavulanate (with or without Rifampin) for Tuberculosis: The COMRADE Randomized, Phase 2A Clinical Trial.Am J Respir Crit Care Med. 2022 May 15;205(10):1228-1235. doi: 10.1164/rccm.202108-1976OC. Am J Respir Crit Care Med. 2022. PMID: 35258443 Free PMC article. Clinical Trial.
-
Synthetic lethality reveals mechanisms of Mycobacterium tuberculosis resistance to β-lactams.mBio. 2014 Sep 16;5(5):e01767-14. doi: 10.1128/mBio.01767-14. mBio. 2014. PMID: 25227469 Free PMC article.
-
Contezolid Harbored Equivalent Efficacy to Linezolid in Tuberculosis Treatment in a Prospective and Randomized Early Bactericidal Activity Study.Infect Drug Resist. 2025 Jan 13;18:261-268. doi: 10.2147/IDR.S499816. eCollection 2025. Infect Drug Resist. 2025. PMID: 39830036 Free PMC article.
-
The chemical biology of new drugs in the development for tuberculosis.Curr Opin Chem Biol. 2010 Aug;14(4):456-66. doi: 10.1016/j.cbpa.2010.04.008. Epub 2010 May 7. Curr Opin Chem Biol. 2010. PMID: 20452813 Free PMC article. Review.
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical